The estimated Net Worth of Douglas M Hunt is at least $2.78 million dollars as of 17 July 2024. Mr Hunt owns over 3,637 units of Puma Biotechnology Inc stock worth over $333,068 and over the last 7 years he sold PBYI stock worth over $307,677. In addition, he makes $2,135,437 as Sr. VP of Regulatory Affairs et Medical Writing & Project Management at Puma Biotechnology Inc.
Mr has made over 33 trades of the Puma Biotechnology Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 3,637 units of PBYI stock worth $13,457 on 17 July 2024.
The largest trade he's ever made was selling 8,358 units of Puma Biotechnology Inc stock on 3 January 2024 worth over $37,527. On average, Mr trades about 1,435 units every 44 days since 2018. As of 17 July 2024 he still owns at least 133,227 units of Puma Biotechnology Inc stock.
You can see the complete history of Mr Hunt stock trades at the bottom of the page.
Douglas Hunt B.Sc., FRAPS is the Sr. VP of Regulatory Affairs, Medical Writing & Project Management at Puma Biotechnology Inc.
As the Sr. VP of Regulatory Affairs et Medical Writing & Project Management of Puma Biotechnology Inc, the total compensation of Mr FRAPS at Puma Biotechnology Inc is $2,135,437. There are 3 executives at Puma Biotechnology Inc getting paid more, with Alan H. Auerbach having the highest compensation of $5,693,423.
Mr FRAPS is 56, he's been the Sr. VP of Regulatory Affairs et Medical Writing & Project Management of Puma Biotechnology Inc since . There are 6 older and 8 younger executives at Puma Biotechnology Inc. The oldest executive at Puma Biotechnology Inc is Jay Moyes, 66, who is the Lead Independent Director.
Douglas's mailing address filed with the SEC is C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 2150, LOS ANGELES, CA, 90024.
Over the last 13 years, insiders at Puma Biotechnology Inc have traded over $168,440,369 worth of Puma Biotechnology Inc stock and bought 2,655,298 units worth $48,866,148 . The most active insiders traders include Capital Partners Gp, L.L.C...., Steven Lo et Troy Edward Wilson. On average, Puma Biotechnology Inc executives and independent directors trade stock every 18 days with the average trade being worth of $60,225. The most recent stock trade was executed by Michael Patrick Miller on 12 August 2024, trading 23,358 units of PBYI stock currently worth $81,519.
we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
Puma Biotechnology Inc executives and other stock owners filed with the SEC include: